[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Gyeongsang National University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100650519","malignant-gastric-outlet-obstruction-study-with-stomach-partitioning-go-part-100650519",false,"NCT07749326","Malignant Gastric Outlet Obstruction Study With Stomach Partitioning (GO-PART)","Conventional Versus Stomach-Partitioning Gastrojejunostomy for Malignant Gastric Outlet Obstruction in Stage IV Gastric Cancer (GO-PART Study, KLASS 16)","GO-PART","Inclusion Criteria:\n\n* Histologically confirmed gastric adenocarcinoma with Gastric Outlet Obstruction (GOO) that is unresectable for cure (e.g., surrounding tissue invasion, localized peritoneal metastasis, distant metastasis)\n\n  * Tumor location confined to the lower one-third (Low body 1\u002F3) of the stomach ③ Age between 20 and 85 years\n\n    * ECOG Performance Status ≤ 2 ⑤ ASA score Class I to III ⑥ Endoscopic or radiologic evidence of obstructive GOO\n\nExclusion Criteria:\n\n* Patients with bowel obstruction due to extensive peritoneal metastasis (P3)\n\n  * Tumor extension beyond the lower one-third into the middle one-third of the stomach, making partitioning difficult ③ Patients requiring emergency surgery for perforation or hemorrhage ④ Severe malnutrition (serum albumin \\\u003C 2.5} g\u002FL) ⑤ Patients currently undergoing pre-operative chemotherapy","ALL","20 Years","85 Years",{"count":21,"type":22},144,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to evaluate whether stomach-partitioning gastrojejunostomy (SPGJ) more effectively reduces postoperative delayed gastric emptying (DGE) compared to conventional gastrojejunostomy (CGJ) in patients with unresectable stage IV gastric cancer accompanied by malignant gastric outlet obstruction (MGOO). This multicenter randomized trial aims to establish a new surgical standard that enhances recovery and quality of life in advanced gastric cancer.\n\nThe main questions are:\n\n1. Does SPGJ significantly decrease DGE compared with CGJ?\n2. Does SPGJ enable faster food tolerance, shorter hospital stay, and earlier chemotherapy? Researchers will compare two arms - SPGJ and CGJ - to determine differences in postoperative gastric emptying, hospital course, complications, and survival outcomes.\n\nParticipants Eligible participants are adults aged 20-85 years with histologically proven unresectable gastric adenocarcinoma limited to the lower third of the stomach and endoscopic or radiologic evidence of obstruction. Patients with total bowel obstruction, middle-third tumor extension, emergency conditions, or severe malnutrition (albumin \\\u003C 2.5 g\u002FL) are excluded.\n\nInterventions\n\n* CGJ arm: Standard laparoscopic gastrojejunostomy using a 60 mm stapler without partitioning.\n* SPGJ arm: Laparoscopic transverse gastric partitioning 5 cm proximal to the tumor with a 2 cm bridge at the lesser curvature, followed by stapled gastrojejunostomy.\n\nAll operations follow standardized training videos and pretrial workshops to ensure consistency across 32 Korean university hospitals.\n\nStudy Design This is a prospective, randomized controlled multicenter trial (KLASS 16). After intraoperative diagnostic laparoscopy confirms eligibility, participants are randomized by a secure web-based block system stratified by hospital. A total of 144 patients (72 per arm) will be enrolled, ensuring 90% statistical power based on expected DGE rates (CGJ 34.6% vs SPGJ 3.8%).\n\nEndpoints\n\n* Primary endpoint: Incidence of DGE within 30 days (ISGPS criteria).\n* Secondary endpoints: Day of oral tolerance (GOO score ≥ 2), hospital stay, Clavien-Dindo ≥ II complications, mechanical obstruction recurrence, 6 and 12 month overall survival, and quality of life.\n\nData Collection and Analysis Data will include postoperative nutrition recovery, complication grades, and survival follow-up. Analyses will utilize Chi square or Fisher's exact test for DGE rates and Kaplan-Meier with log rank testing for survival. Logistic regression will identify DGE risk factors.\n\nDuration Total 3 years: 6 months preparation, 1 year enrollment, 1 year follow up, and 6 months for data analysis and reporting.\n\nExpected Outcomes SPGJ is expected to reduce DGE by \\> 70%, shorten hospital stay by \\~3 days, and enable earlier chemotherapy, thereby improving palliative care outcomes and overall patient quality of life. The KLASS 16 trial will provide the first multicenter, Level I evidence to determine whether SPGJ should replace CGJ as the standard palliative procedure for MGOO.",[28,29],"Stomach Neoplasms","Gastric Outlet Obstruction",[31,32,33],"stomach neoplasm","gastric outlet obstruction","palliative surgery","RECRUITING","2026-08-07",{"date":37,"type":38},"2026-08-11","ACTUAL",{"date":40,"type":38},"2026-08-01",{"date":42,"type":22},"2030-07-31",{"name":44,"class":45},"Gyeongsang National University Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":46},"100646842","phase-4-early-single-antiplatelet-therapy-after-ivus-guided-pci-in-acute-coronary-syndrome-100646842","NCT07684742","Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome","Early Single Antiplatelet Therapy With a Potent P2Y12 Inhibitor After Intravascular Ultrasound-Guided PCI in Patients With Acute Coronary Syndrome: A Multicenter Randomized Controlled Trial","SAPT-ACS","Inclusion Criteria:\n\n1. Age \\>=18 years\n2. Diagnosis of acute coronary syndrome, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or unstable angina (UA)\n3. Successful IVUS-guided PCI with drug-eluting stent implantation\n4. Randomization within 96 hours after PCI\n5. Written informed consent\n\nExclusion Criteria:\n\n1. Planned staged PCI or CABG\n2. PCI failure, including no-reflow, major dissection, or thrombosis\n3. Need for oral anticoagulation\n4. Major bleeding within 30 days\n5. History of hemorrhagic stroke or ischemic stroke within 6 months\n6. Platelet count \\\u003C100,000\u002Fmm3 or WBC count \\\u003C3,000\u002Fmm3\n7. Contraindication to aspirin, ticagrelor, or prasugrel\n8. Life expectancy \\\u003C1 year\n9. Current or potential pregnancy\n10. Investigator deems participation inappropriate","18 Years",{"count":57,"type":22},1900,[59],"PHASE4","This is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular ultrasound (IVUS)-guided drug-eluting stent implantation in patients with acute coronary syndrome. A total of 1,900 patients who achieve complete revascularization after IVUS-guided percutaneous coronary intervention (PCI) and meet the predefined successful IVUS-guided PCI criteria will be randomized in a 1:1 ratio to either the early single antiplatelet therapy group (Early SAPT: ticagrelor or prasugrel monotherapy) or the standard dual antiplatelet therapy group (Standard DAPT: aspirin plus ticagrelor or prasugrel). Randomization will be performed within 96 hours after completion of PCI, and clinical follow-up will be conducted at 1 month, 3 months, 6 months, and 12 months after randomization. The primary endpoints are major adverse cardiovascular events, defined as a composite of all-cause death, myocardial infarction, ischemia-driven target vessel revascularization, and definite or probable stent thrombosis occurring up to 12 months after randomization, and clinically relevant bleeding, defined as Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding occurring up to 12 months after randomization. This study aims to determine whether early P2Y12 inhibitor monotherapy is non-inferior to standard dual antiplatelet therapy (DAPT) for ischemic events and is superior in reducing clinically relevant bleeding.",[62,63,64,65],"Acute Coronary Syndromes","STEMI","NSTEMI","Unstable Angina",[67,68,69,70,71],"Intravascular Ultrasound","Percutaneous Coronary Intervention","Drug-Eluting Stent","Single Antiplatelet Therapy","Dual Antiplatelet Therapy","NOT_YET_RECRUITING","2026-06-29",{"date":75,"type":38},"2026-07-06",{"date":77,"type":22},"2026-07-01",{"date":79,"type":22},"2032-07-01",{"name":44,"class":45},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":46},"100546515","wecare-study-in-gastric-cancer-survivors-100546515","NCT06395935","Wecare Study in Gastric Cancer Survivors","A Multi-center, Prospective, Randomized Study to Evaluate the Usefulness of Applying the Chronic Side Effect Management Platform (Wecare) in Gastric Cancer Survivors","Inclusion Criteria:\n\n* Adult patient (19-75 years) who underwent radical gastrectomy\n\nExclusion Criteria:\n\n* Patients who were unable to undergo regular follow-up, lacked communication, or were deemed unsuitable to participate in this study by the researcher","19 Years","75 Years",{"count":91,"type":22},88,[25],"The KOrean QUality of life in Stomach cancer patients Study group (KOQUSS) made a method (KOQUSS-40) for assessing appropriately the quality of life of gastric cancer patients who have undergone gastrectomy, and developed a digital platform (Wecare) based on KOQUSS-40. In this study, we propose a randomized controlled trial to compare quality of life after gastrectomy in patients with and without smartphone app support.",[95],"Gastric Cancer","2024-10-10",{"date":98,"type":38},"2024-10-15",{"date":100,"type":38},"2024-04-01",{"date":102,"type":22},"2026-03-30",{"name":44,"class":45},""]